Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-023916
Filing Date
2025-09-08
Accepted
2025-09-08 20:05:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 15361
2 JOINT FILING AGREEMENT ex-99-09092025_120945.htm EX-99.1 4124
  Complete submission text file 0001415889-25-023916.txt   21180
Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 (650) 285-4270
Samsara BioCapital, L.P. (Filed by) CIK: 0001699737 (see all company filings)

EIN.: 813958301 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087
Business Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 (888) 378-6240
Mineralys Therapeutics, Inc. (Subject) CIK: 0001933414 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94000 | Film No.: 251301400
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)